Linus Pauling was a famous scientist who won two Nobel prizes. He studied how atoms stick together and how proteins are built. Late in his life, he became known for a different idea: that very large amounts of vitamin C could help people with cancer. Many doctors did not believe him. When Pauling died of cancer at 93, people wondered if his fame in chemistry meant he could also know everything about medicine.
Today, scientists are looking again at vitamin C and cancer. New research shows that, under certain conditions, vitamin C can act more like a drug than a simple vitamin.
In the 1970s, Pauling worked with a Scottish doctor named Ewan Cameron. They gave patients with advanced, untreatable cancer huge doses of vitamin C. First they used an IV drip, then they gave pills. The patients who got vitamin C seemed to live longer and feel better than similar patients who did not receive it. Some even thought they might live many times longer.
Later, two large studies at the Mayo Clinic tested only vitamin C pills. Those trials showed no benefit – the patients lived just as long as those who took a placebo. Most cancer doctors took this as proof that vitamin C does not help.
What the early trials missed was the way vitamin C was given. Pauling used an IV drip, while the Mayo studies used only pills. This matters because our gut can only absorb a limited amount of vitamin C. After a modest daily dose, the body stops taking in more. Swallowing many pills does not raise blood levels much.
In contrast, an IV drip can push vitamin C levels in the blood to tens or hundreds of times higher than pills ever can. At those high levels, vitamin C behaves differently inside the body.
At normal levels, vitamin C works as an antioxidant – it cleans up harmful molecules and protects cells. At very high levels, especially around tumors, it can act like a weak chemotherapy agent.
Lab studies show that high‑dose vitamin C creates hydrogen peroxide, a chemical that can damage cells. Cancer cells are already stressed and have weak defenses, so the extra hydrogen peroxide can push them over the edge, damaging their DNA and energy factories, and causing them to die. Normal cells, which are less stressed, are more likely to survive.
What Recent Studies Show
Human research is still early and mixed. Small trials have given high‑dose vitamin C IV to patients with hard‑to‑treat cancers such as ovarian, pancreatic, and brain tumors. Many patients can receive the treatment several times a week without serious side effects. However, people with poor kidney function or rare genetic conditions can have problems, so the therapy is not a simple wellness drip.
Some studies suggest that adding vitamin C IV to chemotherapy may extend survival a little or lessen side effects like fatigue, pain, and nausea. Other studies find no clear benefit. Because the trials are small and different from each other, scientists cannot draw firm conclusions yet.
One consistent finding is improved quality of life. Patients who receive vitamin C alongside chemotherapy often report feeling less tired and in less pain. For someone with advanced cancer, feeling better matters a lot, even if the treatment does not cure the disease.
Laboratory work also hints at subtler roles. Vitamin C helps enzymes that control how our DNA is marked and read, and it influences cell division and response to low oxygen – all important in cancer growth. In some experiments, high vitamin C levels make cancer cells grow less aggressively and become more sensitive to other treatments. Early research even suggests that vitamin C might help the immune system recognize and attack tumors, though this is still speculative.
Was Pauling Right?
In the end, Pauling was partly right and partly wrong. He was wrong to claim that vitamin C pills could cure cancer – large, well‑designed trials have not shown that. He was also wrong to say vitamin C could heal many illnesses.
However, he was not entirely wrong to suspect that very high doses given by IV could have a special effect on cancer. Modern science confirms that IV vitamin C reaches much higher blood levels than pills and can act differently inside the body.
What we still lack are big, randomized trials that prove high‑dose IV vitamin C clearly extends life for most cancer patients. Until such evidence appears, the treatment should be considered experimental – promising enough to study, but not proven enough to replace standard care. Any use should happen in clinical trials or under careful medical supervision, not in unregulated clinics selling “immune boosts.”
The story of vitamins and cancer continues to evolve. It reminds us that scientific ideas rarely move in straight lines: a bold hypothesis, early flawed studies, strong criticism, and later careful re‑examination.